Cryptococcus neoformans and Cryptococcus gattii species complexes cause
meningoencephalitis with high fatality rates and considerable morbidity, particularly in …

Cryptococcal meningitis is a leading cause of morbidity and mortality globally, especially in
people with advanced HIV disease. Cryptococcal meningitis is responsible for nearly 20% of …

Background Amphotericin B is the gold standard treatment for severe mycoses. A new orally
delivered, less-toxic formulation of amphotericin has been developed. Methods In our …

Abstract The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in
eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal …

Cryptococcal meningitis persists as a significant source of morbidity and mortality in persons
with HIV/AIDS, particularly in sub-Saharan Africa. Despite increasing access to …

Cryptococcosis has been one of the most common opportunistic infections and causes of
mortality among HIV-infected patients, especially in resource-limited countries. Cryptococcal …

Background Cryptococcal meningitis (CM) is a leading cause of adult meningitis in countries
with a high burden of HIV. It has remained a significant cause of morbidity and mortality in …

Background Increased intracranial pressure (ICP) frequently complicates cryptococcal
meningitis. Therapeutic lumbar punctures (LPs) have acute survival benefits in the first …

Background Cryptococcal meningitis and tuberculosis are both important causes of death in
persons with advanced human immunodeficiency virus (HIV)/acquired immunodeficiency …

Background In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA)
of Cryptococcus clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint …